单克隆抗体适应中度至重度的亚托皮性皮炎:看看第三阶段及之后的情况
Eden David1, Kelly Hawkins1,2, Neda Shokrian1,2
1Department of Dermatology, Icahn school of Medicine at Mount Sinai, New York, NY, USA.
Expert opinion on biological therapy
|June 18, 2024
概括
新的单克隆抗体治疗方法正在出现,用于治疗阿托皮性皮肤炎 (AD),提供有针对性的方法. 了解它们的机制是针对阿兹海默症患者个性化医学的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对亚托匹性皮肤炎 (AD) 病原体的理解有了显著的进步.
- 这一进展刺激了针对阿尔茨海默氏症的向单克隆抗体疗法的开发.
研究的目的:
- 审查当前关于阿尔茨海默氏症先进单克隆抗体治疗的临床和分子数据.
- 突出这些疗法的生物作用机制和免疫调节.
主要方法:
- 对第三期试验和最近批准的AD单克隆抗体的文献综述.
- 对生物基础和免疫特征调节的分析.
- 综合最新的临床和分子数据.
主要成果:
- 单克隆抗体代表了AD的快速发展的治疗前沿.
- 这些向治疗为个性化医疗方法提供了潜力.
- 了解药物机制对于优化患者选择和结果至关重要.
结论:
- 随着AD治疗的不断发展,包括有希望的向单克隆抗体.
- 个性化治疗策略变得越来越可行.
- 对特定药物机制的进一步研究将完善AD管理.
更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115


